PHASE 2, OPEN-LABEL, MULTICENTER, RANDOMIZED STUDY OF PD 0332991 (ORAL CDK 4/6 INHIBITOR) MONOTHERAPY AND PD 0332991 IN COMBINATION WITH THE ENDOCRINE THERAPY TO WHICH THE PATIENT HAS PROGRESSED IN THE PREVIOUS LINE FOR ER-POSITIVE, HER2-NEGATIVE POST-MENOPAUSAL ADVANCED BREAST CANCER PATIENTS

Trial Profile

PHASE 2, OPEN-LABEL, MULTICENTER, RANDOMIZED STUDY OF PD 0332991 (ORAL CDK 4/6 INHIBITOR) MONOTHERAPY AND PD 0332991 IN COMBINATION WITH THE ENDOCRINE THERAPY TO WHICH THE PATIENT HAS PROGRESSED IN THE PREVIOUS LINE FOR ER-POSITIVE, HER2-NEGATIVE POST-MENOPAUSAL ADVANCED BREAST CANCER PATIENTS

Completed
Phase of Trial: Phase II

Latest Information Update: 03 Aug 2017

At a glance

  • Drugs Palbociclib (Primary) ; Anastrozole; Exemestane; Fulvestrant; Letrozole
  • Indications Advanced breast cancer
  • Focus Therapeutic Use
  • Acronyms TREnd
  • Most Recent Events

    • 31 Jul 2017 Status changed from active, no longer recruiting to completed.
    • 10 Jun 2017 Biomarkers information updated
    • 02 Jun 2017 Primary endpoint has been met. (Incidence of complete response (CR), partial response (PR) or stable disease (SD) 24 weeks (clinical benefit)) as per results presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top